Published in Br J Cancer on September 16, 2008
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol (2010) 1.55
Novel diagnostic biomarkers for prostate cancer. J Cancer (2010) 1.36
Tumor markers for hepatocellular carcinoma. Mol Clin Oncol (2013) 1.35
Cancer biomarker discovery: the entropic hallmark. PLoS One (2010) 1.26
The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet (2013) 1.25
The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget (2014) 1.16
Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol (2015) 1.00
GOLPH2 expression in renal cell cancer. BMC Urol (2008) 0.95
Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype. Br J Cancer (2010) 0.93
Golgi phosphoprotein 2 in physiology and in diseases. Cell Biosci (2012) 0.92
Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel. Cancer Metastasis Rev (2014) 0.89
Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark (2012) 0.88
GOLPH2 expression may serve as diagnostic marker in seminomas. BMC Urol (2010) 0.86
Emerging biomarkers of prostate cancer (Review). Oncol Rep (2012) 0.86
Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma. Biomark Cancer (2016) 0.85
Emerging roles of human prostatic Acid phosphatase. Biomol Ther (Seoul) (2013) 0.84
The androgen-regulated Calcium-Activated Nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro. Am J Pathol (2011) 0.84
A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants. PLoS One (2013) 0.84
A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma. Oncotarget (2015) 0.83
GP73 is down-regulated in gastric cancer and associated with tumor differentiation. World J Surg Oncol (2013) 0.82
Golgi protein 73 activation of MMP-13 promotes hepatocellular carcinoma cell invasion. Oncotarget (2015) 0.81
Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA. J Biomed Res (2012) 0.81
Current early diagnostic biomarkers of prostate cancer. Asian J Androl (2014) 0.81
Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues. Biomed Res Int (2013) 0.81
Single foci prostate cancer: current diagnosis and management. Curr Urol (2013) 0.80
Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer. Virchows Arch (2011) 0.79
Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia. Virchows Arch (2014) 0.78
[Immunohistochemical algorithms in prostate diagnostics: what's new?]. Pathologe (2009) 0.77
TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy. Virchows Arch (2015) 0.77
Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion. Br J Cancer (2015) 0.76
Extending the tissue microarray data exchange specification for inclusion of data analysis results. J Pathol Inform (2011) 0.76
Golgi-Related Proteins GOLPH2 (GP73/GOLM1) and GOLPH3 (GOPP1/MIDAS) in Cutaneous Melanoma: Patterns of Expression and Prognostic Significance. Int J Mol Sci (2016) 0.75
GP73-regulated oncolytic adenoviruses possess potent killing effect on human liver cancer stem-like cells. Oncotarget (2016) 0.75
A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential. J Biomark (2014) 0.75
Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. Oncotarget (2016) 0.75
[High-grade prostatic intraepithelial neoplasia: the only accepted prostate cancer precursor lesion]. Pathologe (2011) 0.75
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
ArrayExpress--a public database of microarray experiments and gene expression profiles. Nucleic Acids Res (2006) 8.92
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res (2001) 4.51
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst (2003) 3.73
Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res (2001) 3.45
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res (2008) 3.35
p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol (2000) 3.20
Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res (2003) 2.91
Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A (2005) 2.70
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol (2005) 2.70
Gene expression analysis of prostate cancers. Mol Carcinog (2002) 2.51
Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol (2006) 2.41
Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res (2006) 2.40
Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res (2000) 1.98
GP73, a novel Golgi-localized protein upregulated by viral infection. Gene (2000) 1.96
Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol (2001) 1.87
P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol (2001) 1.86
Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology (2002) 1.68
Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol (2004) 1.65
Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB J (2004) 1.51
Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol (2005) 1.51
Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic (2007) 1.48
Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res (2006) 1.33
Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res (1985) 1.32
Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol (2004) 1.20
N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem (2008) 1.14
Biomarkers for prostate cancer detection. J Urol (2007) 1.14
Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1A CtBP interaction domain. Virology (2002) 1.07
How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol (2004) 1.06
The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Prostate (2006) 1.00
Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol (2003) 0.99
P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens. Am J Clin Pathol (2004) 0.84
Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score. Histopathology (2007) 0.84
Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. Clin Cancer Res (2006) 0.84
Prostatic adenocarcinoma with atrophic features: a study of 202 consecutive completely embedded radical prostatectomy specimens. Am J Clin Pathol (1998) 0.79
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol (2000) 7.94
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol (2001) 3.83
Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res (1999) 3.41
Betaine improves the PCR amplification of GC-rich DNA sequences. Nucleic Acids Res (1997) 3.32
Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol (2001) 3.09
Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst (2001) 2.93
Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol (2001) 2.91
Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med (1997) 2.88
Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res (1999) 2.79
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer (2008) 2.67
ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol (2004) 2.45
CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest (1997) 2.39
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A (1998) 2.29
Inferring tree models for oncogenesis from comparative genome hybridization data. J Comput Biol (1999) 2.25
Probing proton dynamics in molecules on an attosecond time scale. Science (2006) 2.24
Acute right-sided heart failure due to hemorrhage into a pericardial cyst. Ann Thorac Surg (1997) 2.24
Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol (2001) 2.20
European and US publications in the 50 highest ranking pathology journals from 2000 to 2006. J Clin Pathol (2007) 2.20
Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis (2007) 2.16
Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood. Int J Cancer (1997) 2.11
Karyomegalic interstitial nephritis: further support for a distinct entity and evidence for a genetic defect. Am J Kidney Dis (1995) 2.01
Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest (1996) 2.00
Health hazards posed by feral pigeons. J Infect (2004) 1.93
Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): An autopsy study on 367 patients. Urol Int (1999) 1.92
Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary cells. Carcinogenesis (1992) 1.92
Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res (1997) 1.89
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology (2000) 1.82
High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol (2000) 1.82
Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst (1999) 1.81
Primary cytomegalovirus infection in an outpatient setting--laboratory markers and clinical aspects. Infection (2003) 1.78
Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res (1997) 1.76
The mechanical effect of blocking screws ("Poller screws") in stabilizing tibia fractures with short proximal or distal fragments after insertion of small-diameter intramedullary nails. J Orthop Trauma (1999) 1.75
Regulation of RssB-dependent proteolysis in Escherichia coli: a role for acetyl phosphate in a response regulator-controlled process. Mol Microbiol (1998) 1.74
Pathogenesis and immune responses in gnotobiotic calves after infection with the genogroup II.4-HS66 strain of human norovirus. J Virol (2007) 1.70
Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol (2001) 1.67
Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer (2000) 1.65
High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res (2001) 1.64
Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis (1989) 1.64
Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol (2001) 1.62
Role of mitochondria and C-terminal membrane anchor of Bcl-2 in Bax induced growth arrest and mortality in Saccharomyces cerevisiae. FEBS Lett (1996) 1.59
Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J Natl Cancer Inst (2001) 1.59
Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta (2001) 1.58
Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis. Ann Neurol (2001) 1.57
Subcutaneous crystal-storing histiocytosis associated with lymphoplasmacytic lymphoma (immunocytoma) Pathol Res Pract (1996) 1.57
Distance-based reconstruction of tree models for oncogenesis. J Comput Biol (2000) 1.55
Phylogenetic analysis of swine influenza viruses recently isolated in Korea. Virus Genes (2008) 1.52
CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer (2003) 1.49
Beta-trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range. Clin Chem (1999) 1.49
Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int J Hyperthermia (2007) 1.48
Isoforms of prostate-specific antigen in serum: a result of the glycosylation process in dysplastic prostatic cells? Prostate (1996) 1.46
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst (1999) 1.46
Quality indicators in breast cancer care. Eur J Cancer (2010) 1.46
Construction of evolutionary tree models for renal cell carcinoma from comparative genomic hybridization data. Cancer Res (2000) 1.45
Isolation and phylogenetic analysis of H1N1 swine influenza virus isolated in Korea. Virus Res (2006) 1.45
COLOR II. A randomized clinical trial comparing laparoscopic and open surgery for rectal cancer. Dan Med Bull (2009) 1.45
Metastatic primitive neuroectodermal tumor of the kidney in adults. Eur Urol (2001) 1.44
Telemicroscopy via the internet. Nature (1998) 1.44
Small-cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 10q, 13q and 17p. Br J Cancer (1997) 1.44
The use of Poller screws as blocking screws in stabilising tibial fractures treated with small diameter intramedullary nails. J Bone Joint Surg Br (1999) 1.44
Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol (2001) 1.43
Properties and purification of an active biotinylated lactose permease from Escherichia coli. Proc Natl Acad Sci U S A (1993) 1.43
[Inter-disciplinary European guidelines on surgery of severe obesity]. Vnitr Lek (2008) 1.42
PhaF, a polyhydroxyalkanoate-granule-associated protein of Pseudomonas oleovorans GPo1 involved in the regulatory expression system for pha genes. J Bacteriol (1999) 1.40
TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol (2009) 1.40
Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ (2006) 1.39
Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer (2004) 1.39
[Off-label=off-legal=illegal?]. Pneumologie (2005) 1.39
Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer (2000) 1.38
High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer (2007) 1.37
Multiple sclerosis and Chlamydia pneumoniae. Ann Neurol (2000) 1.37
Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology (2000) 1.36
Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res (2001) 1.35
Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol (1998) 1.34
Spectrum of congenital heart defects and extracardiac malformations associated with chromosomal abnormalities: results of a seven year necropsy study. Heart (1999) 1.33
Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate. Pediatr Nephrol (1999) 1.32
The lactose permease meets Frankenstein. J Exp Biol (1994) 1.32
Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis (1999) 1.30
Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol (1996) 1.29
Expression of AGR2 in non small cell lung cancer. Histol Histopathol (2007) 1.26
Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. Am J Pathol (1999) 1.25
Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer (2003) 1.25
Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol (1998) 1.24
Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer (2007) 1.23
Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate (2001) 1.23
Mobilization of small plasmids in Bacillus thuringiensis subsp. israelensis is accompanied by specific aggregation. J Bacteriol (1993) 1.21
Cysteine 148 in the lactose permease of Escherichia coli is a component of a substrate binding site. 1. Site-directed mutagenesis studies. Biochemistry (1994) 1.20